Cite
HARVARD Citation
Papadopoulou, E. et al. (2021). Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Journal of hypertension. 39 (4), pp. 749-758. [Online].